China Allows Firms to Price Drugs Based on Value, R&D, and Risks

Select Language:

China is set to improve its initial pricing approach for newly approved medicines, enabling pharmaceutical companies to establish prices based on the therapeutic importance and the significant R&D investments and risks involved in developing cutting-edge innovative drugs.

Manufacturers will now have the autonomy to determine the starting prices for new medicines by taking into account factors such as clinical value, demand and supply in the market, the competitive landscape, and social affordability, as outlined in a new policy document from the State Council’s General Office.

For innovative medications that demonstrate strong innovation and clinical relevance, the government encourages companies to set launch prices that reflect their substantial R&D costs and associated risks, and to keep those prices stable for a designated period. Future price adjustments may be considered based on actual clinical outcomes.

This policy clarifies previous uncertainties surrounding independent drug pricing. A respected academic from Tsinghua University explained that, although most new drugs are initially priced by the companies before they are included in the national insurance scheme, the criteria for pricing before were vague and inconsistent. The new guidelines explicitly base pricing on clinical value, aligned with high research and development expenses and risks.

The term “high investment, high risk” signifies that regulators allow innovative drug manufacturers to incorporate R&D costs and the risks of failure into their pricing assessments. Additionally, companies should prioritize patient benefits when evaluating the clinical significance of their products.

Allowing prices to remain relatively stable for a period after market entry provides safeguard protections for patent-protected drugs, an expert noted.

This revised mechanism signals a move toward a more market-oriented drug pricing system in China, fostering a more supportive policy environment for innovative medicines.